MARINE MICROBE-DERIVED LEADS FOR ALZHEIMERS DISEASE

描述：(逐字摘自申请者的摘要)这一目标 应用是从海洋微生物中引入新的药效团 治疗阿尔茨海默病(AD)的潜在药物。其中一个主要的 阿尔茨海默病的组织病理学特征是形成老年斑 特定的神经元病灶。这些斑块，大多由不溶物质组成 神经细胞和支持(神经胶质)细胞产生的Anyloid-beta肽(Abeta)， 与阿尔茨海默病的神经细胞死亡有关。AD研究的一个主要焦点 涉及到寻找治疗药物，可以减少 不溶的阿贝塔。Oceanix生物科学公司正在努力发现新的 以及来自海洋微生物的专有药效团。研究计划包括 为了在生物测试中测试这些微生物的不同提取物的Abeta 人神经胶质瘤(H4)细胞。在H4中发现的Abeta产生的抑制剂 筛选将在次级筛选中使用原代神经元培养进行测试 (大鼠)。这些细胞产生的Abeta将与已知的 海洋微生物提取物筛选前Abeta的影响因素。提取物 还将进行细胞毒性和细胞凋亡测试。 建议的商业应用： 我们提出的商业应用是这个研究计划的结果，是 与治疗阿尔茨海默病的新药开发有关 疾病。有希望的新化学实体将被进一步跟踪，看看它们是否 是适合人类使用的候选药物。

DESCRIPTION: (Verbatim from the Applicant's Abstract) The goal of this application is to introduce novel pharmacophores from marine microorganisms as potential therapeutic agents for Alzheimer's Disease (AD). One of the major histopathological hallmarks of AD is the formation of senile plaques present in specific neuronal foci. These plaques, mostly composed of insoluble anyloid-beta peptides (Abeta) produced in neurons and supporting (glial) cells, are associated with neuronal cell death in AD. A major focus of AD research involves a search for therapeutic agents that can reduce the formation of insoluble Abeta. Oceanix Biosciences Corp is making efforts to discover novel and proprietary pharmacophores from marine microbes. The research plan included to test different extracts from these microorganisms in a bioassay for Abeta in human neuroglioma (H4) cells. Inhibitors of Abeta production found in the H4 screen will be tested in a secondary screen using primary neuronal cultures (rat). Production of Abeta from these cells will be validated with known affectors of Abeta prior to screening marine microorganism extracts. Extracts will also be tested for cytotoxicity and apoptosis. PROPOSED COMMERCIAL APPLICATION: The commercial application we propose are a result of this research plan, are related to the development of new pharmaceuticals for treating Alzheimer's Disease. Promising new chemical entities will be followed further to see if they are appropriate drug candidates for human use.